Cargando…
DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation
Approximately 10% of human colorectal cancer (CRC) are associated with activated BRAFV600E mutation, typically in absence of APC mutation and often associated with a CpG island methylator (CIMP) phenotype. To protect from cancer, normal intestinal epithelial cells respond to oncogenic BRAFV600E by a...
Autores principales: | MacKenzie, Douglas J., Robertson, Neil A., Rather, Iqbal, Reid, Claire, Sendzikaite, Gintare, Cruickshanks, Hazel, McBryan, Tony, Hodges, Andrew, Pritchard, Catrin, Blyth, Karen, Adams, Peter D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000804/ https://www.ncbi.nlm.nih.gov/pubmed/32058953 http://dx.doi.org/10.1016/j.isci.2020.100838 |
Ejemplares similares
-
Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021) -
Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers
por: Ukkola, Iiris, et al.
Publicado: (2022) -
BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019) -
Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023) -
A DNMT3A PWWP mutation leads to methylation of bivalent chromatin and growth retardation in mice
por: Sendžikaitė, Gintarė, et al.
Publicado: (2019)